About us
ITCC Centers
ITCC Associated Networks
ITCC Clinical Trials
Contact us
Academia
Industry
Advocates

Why ITCC

Innovative Therapies for Children and Adolescents with Cancer: Pioneering Breakthroughts.
Content of page
Why ITCC Our Commitment

Why ITCC

Innovative Therapies for Children and Adolescents with Cancer: Pioneering Breakthroughts

The landscape of innovative therapies for children and adolescents with cancer is rapidly evolving. We are witnessing remarkable progress in introducing safe and effective new treatments for young patients.

Over the past decade, significant advancements in therapeutic innovations have transformed the field of paediatric oncology. Thanks to cutting-edge sequencing techniques, we now have a deeper understanding of the biology underlying various childhood cancers. This knowledge has paved the way for creating personalized tumor molecular profiles, guiding precise and tailored treatments for each child. Led by ITCC and its members, Europe has been at the forefront of establishing this groundbreaking approach.

As a well-established and internationally recognized organization in the field of paediatric oncology drug development, ITCC is dedicated to harnessing the power of science and technology for data analysis. Our mission is to unravel the biology of paediatric tumors, identifying potential therapeutic targets for specific drugs, and uncovering the mechanisms through which these tumors evade the immune system.

Our Commitment

ITCC was created in 2003 and in January 2011 it was established as a European Category 1 Network for Paediatric Research at the European Medicines Agency (EnprEMA).

1
Scientific Prioritization: We increase the likelihood of introducing potentially effective drugs into pediatric development by leveraging our extensive knowledge of tumor biology and enhanced preclinical evaluations.
2
Swift Initiation of Paediatric Studies: By aligning with the developments in adult therapies and pioneering drugs tailored to paediatric malignancies, we fast-track the initiation of paediatric studies.
3
Combination Therapies: We accelerate the development of combination therapies, harnessing the power of synergistic treatments to maximize their impact on young patients.
4
First Line Treatments for High-Risk Diseases: Time is of the essence in the fight against cancer. ITCC is committed to rapidly implementing new therapies in first-line treatments for high-risk diseases, aiming to increase the probability of curing more children at a faster pace.

Subscribe to our Newsletter

Write your email address and tell us what type of information you would like to receive. We will send you all the latest updates in that area at ITCC.
Subscribe